Low-dose aspirin to prevent blood flow problems in giant cell arteritis
Tests whether a future aspirin study is workable in people with giant cell arteritis.
Plain-language title generated from the registry record
Registry title: Aspirin for the Prevention of Ischemic Complications in Giant Cell Arteritis
Key facts
- Where
- Montreal, CanadaSee the site
- Phase
- Phase 3
Where in Canada
- Vasculitis Clinic, Hôpital du Sacré-Coeur de MontréalMontreal, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
- Trial code
- NCT07908082
- Record updated
- 30 October 2026
- Original description
The ASPIRE-GCA Pilot trial will assess the feasibility of a future randomized controlled trial (RCT) evaluating the efficacy of low-dose ASA in preventing ischemic complications in patients with Giant Cell Arteritis (GCA).Read full original descriptionShow less
Aspirin for the Prevention of Ischemic-Related Events in Giant Cell Arteritis Pilot (ASPIRE-GCA Pilot)
The ASPIRE-GCA Pilot trial will assess the feasibility of a future randomized controlled trial (RCT) evaluating the efficacy of low-dose ASA in preventing ischemic complications in patients with Giant Cell Arteritis (GCA).
ASPIRE-GCA Pilot builds on extensive preparatory work and the findings from this study will inform key feasibility outcomes, including recruitment rate, study-drug delivery and treatment initiation, medication adherence, participant retention, and completeness of follow-up data.
Inclusion: Adults with newly diagnosed GCA (≤30 days since diagnosis); GCA fulfilling the 2022 ACR-EULAR Classification Criteria for GCA, supported by positive temporal artery histology, or compatible cranial or large-vessel imaging; Initiation of standard-of-care treatment for GCA, with or without intravenous glucocorticoids; Ability to provide informed consent and participate in virtual study procedures.
Exclusion: Established indication for antiplatelet therapy (e.g., prior or current myocardial infarction, ischemic stroke, transient ischemic attack, or known coronary, cerebrovascular, or peripheral arterial disease); Presence of a condition that, in the investigator's opinion, is expected to limit survival to less than 1 year; All-cause bilateral permanent vision loss during the screening period; Chronic use of therapeutic anticoagulation at baseline; Any contraindication to low-dose ASA according to the product monograph.